{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:01:38Z","timestamp":1774620098905,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00718-z","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:45:34Z","timestamp":1771667134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiological and economic impact of pre-exposure prophylaxis with targeted immunotherapies for COVID-19 among immunosuppressed patients in Argentina"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-1063","authenticated-orcid":false,"given":"Carolina","family":"Moreno-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3029-4439","authenticated-orcid":false,"given":"Federico","family":"Rodr\u00edguez Cairoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Luxardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-5022","authenticated-orcid":false,"given":"Federico","family":"Augustovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Espinola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"718_CR1","unstructured":"WHO Coronavirus. World Health Organization Coronavirus (COVID-19) Dashboard. Available from: https:\/\/covid19.who.int\/. Dashboard [Internet]. [cited 2023 Jan 29 (COVID-19)."},{"key":"718_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/CEOR.S338225","volume":"14","author":"F Richards","year":"2022","unstructured":"Richards F, Kodjamanova P, Chen X, Li N, Atanasov P, Bennetts L, et al. Economic burden of COVID-19: a systematic review. Clinicoecon Outcomes Res. 2022, Apr, 28;14:293\u2013307.","journal-title":"Clinicoecon Outcomes Res"},{"key":"718_CR3","unstructured":"Argentina. WHO Coronavirus disease (COVID-19) Dashboard with vaccination data [Internet]. [https:\/\/covid19.who.int\/region\/amro\/country\/ar. cited 2023 Jan 29]. Available from."},{"key":"718_CR4","unstructured":"Mathieu E, Ritchie H, Rod\u00e9s-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus pandemic (COVID-19). Our world in data [Internet]. 2020 Mar 5. https:\/\/ourworldindata.org\/coronavirus. cited 2023 Feb 6]; Available from."},{"key":"718_CR5","unstructured":"Argentina.gob.ar [Internet]. Direcci\u00f3n de Estad\u00edsticas e Informaci\u00f3n de la Salud. Available from: 2020. https:\/\/www.argentina.gob.ar\/salud\/deis. cited 2023 Sep 19."},{"issue":"1","key":"718_CR6","doi-asserted-by":"publisher","first-page":"e0260733","DOI":"10.1371\/journal.pone.0260733","volume":"17","author":"SK Korang","year":"2022","unstructured":"Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, et al. Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials. PLoS One. 2022, Jan, 21;17(1):e0260733.","journal-title":"PLoS One"},{"key":"718_CR7","doi-asserted-by":"publisher","first-page":"e068632","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYB Lee","year":"2022","unstructured":"Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022, Mar, 2;376:e068632.","journal-title":"BMJ"},{"issue":"10360","key":"718_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","volume":"400","author":"U Agrawal","year":"2022","unstructured":"Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022, Oct, 15;400(10360):1305\u201320.","journal-title":"Lancet"},{"issue":"10","key":"718_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S1473-3099(22)00416-9","volume":"22","author":"GA Herman","year":"2022","unstructured":"Herman GA, O\u2019Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2022, Oct;22(10):1444\u201354.","journal-title":"Lancet Infect Dis"},{"key":"718_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijid.2023.01.019","volume":"129","author":"S Naggie","year":"2023","unstructured":"Naggie S, Milstone A, Castro M, Collins SP, Lakshmi S, Anderson DJ, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial healthcare worker exposure response and outcomes of Hydroxychloroquine (HERO-HCQ). Int J Infect Dis. 2023, Apr;129:40\u201348.","journal-title":"Int J Infect Dis"},{"key":"718_CR11","unstructured":"FDA. fact sheet For healthcare providers: emergency use authorization for evusheld [Internet]. Available fromhttps:\/\/www.fda.gov\/media\/154701\/download. [cited 2023 Sep 27]."},{"key":"718_CR12","unstructured":"European Medicines Agency [Internet]. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evusheld. cited 2023 Feb 6]. Evusheld-European Medicines Agency. Available from."},{"key":"718_CR13","doi-asserted-by":"crossref","unstructured":"Hirsch C, Park YS, Piechotta V, Chai KL, Estcourt LJ, Monsef I, et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022 Jun, 17;6(6): CD014945.","DOI":"10.1002\/14651858.CD014945.pub2"},{"key":"718_CR14","unstructured":"World Health Organization. [Internet]. [https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants. cited 2023 Feb 10]. World Health Organization. Tracking SARS-CoV-2 variants. Available from."},{"key":"718_CR15","unstructured":"European Centre for Disease Prevention and Control [Internet]. [https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern. cited 2023 Feb 10]. European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 26 January 2023. Available from."},{"key":"718_CR16","unstructured":"EMA. European Medicines Agency. 2022. https:\/\/www.ema.europa.eu\/en\/news\/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2. cited 2023 Feb 6]. European Medicines Agency. ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2. Available from."},{"key":"718_CR17","unstructured":"Food and Drug Administration. FDA. emergency use authorization for evusheldtm (tixagevimab co-packaged with cilgavimab) [Internet]. [ https:\/\/www.fda.gov\/media\/154701\/download. cited 2023 Jun 2]. Available from."},{"key":"718_CR18","unstructured":"Center for Drug Evaluation, Research. U.S. Food and Drug Administration. FDA; [FDA announces Evusheld is not currently authorized for emergency use in the U.S. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us. cited 2023 Jan 30."},{"key":"718_CR19","unstructured":"Update on US Food and Drug Administration Emergency Use Authorization of EVUSHELD [Internet]. 2023. https:\/\/www.astrazeneca-us.com\/media\/press-releases\/2023\/update-on-us-food-and-drug-administration-emergency-use-authorization-of-evusheld.html. cited 2023 Feb 6]. Available from."},{"issue":"23","key":"718_CR20","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for Prevention of covid-19. N Engl J Med. 2022, Jun, 9;386(23):2188\u2013200.","journal-title":"N Engl J Med"},{"issue":"4","key":"718_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jama.2021.24931","volume":"327","author":"Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19","year":"2022","unstructured":"Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19. JAMA. 2022, Jan, 25;327(4):384\u201385.","journal-title":"JAMA"},{"key":"718_CR22","doi-asserted-by":"publisher","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Stein N, Saliba W. Effectiveness of evusheld in immunocompromised patients: propensity score-matched analysis. Clin Infect Dis [Internet]. 2022, Oct, 31; Available from: https:\/\/doi.org\/10.1093\/cid\/ciac855.","DOI":"10.1093\/cid\/ciac855"},{"key":"718_CR23","doi-asserted-by":"publisher","unstructured":"Sutton K, Miller P, Branscombe N, Mittal M, Browne C, Arnetorp S, et al. EE572 cost-effectiveness of AZD7442 (tixagevimab and cilgavimab) for pre-exposure prophylaxis against COVID-19 in the immunocompromised population [Internet]. vol. Value Health. 2022;25:S168. Available from: https:\/\/doi.org\/10.1016\/j.jval.2022.09.812.","DOI":"10.1016\/j.jval.2022.09.812"},{"issue":"3","key":"718_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40258-023-00796-7","volume":"21","author":"W Rattanavipapong","year":"2023","unstructured":"Rattanavipapong W, Poonsiri C, Isaranuwatchai W, Iamsirithaworn S, Apakupakul J, Sonthichai C, et al. Economic Evaluation of evusheld for preexposure Prevention of COVID-19 in high-risk populations: early evidence from Thailand. Appl Health Econ Health Policy. 2023, May;21(3):511\u201322.","journal-title":"Appl Health Econ Health Policy"},{"key":"718_CR25","unstructured":"Centers for Disease Control and Prevention. Clinical guidance for COVID-19 vaccination [Internet]. 2023. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html. cited 2023 Feb 9]. Available from."},{"key":"718_CR26","unstructured":"Australian Government. Department of Health and Age Care. [Internet]. Australian Government. ATAGI recommendations on the use of a third primary dose of COVID-19 vaccine in individuals who are severely immunocompromised. Available from: https:\/\/www.health.gov.au\/resources\/publications\/atagi-recommendations-on-the-use-of-a-third-primary-dose-of-covid-19-vaccine-in-individuals-who-are-severely-immunocompromised?language=en."},{"key":"718_CR27","unstructured":"Instituto Nacional Central \u00danico Coordinador de Ablaci\u00f3n e Implante. [Internet]. [Sistema Nacional de Informaci\u00f3n de Procuraci\u00f3n y Trasplante de la Rep\u00fablica Argentina. Available from: https:\/\/sintra.incucai.gov.ar\/intro\/. cited 2023 Mar 6."},{"key":"718_CR28","unstructured":"INDEC. Instituto Nacional de Estadistica y Censos de la REPUBLICA ARGENTINA. INDEC: Instituto Nacional de Estad\u00edstica y Censos de la Rep\u00fablica Argentina [Internet]. [https:\/\/www.indec.gob.ar\/indec\/web\/Nivel4-Tema-2-24-84. cited 2023 Mar 7]. Available from."},{"issue":"3","key":"718_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/23288604.2018.1477537","volume":"4","author":"A Rubinstein","year":"2018","unstructured":"Rubinstein A, Zerbino MC, Cejas C, L\u00f3pez A. Making universal Health care effective in Argentina: a blueprint for Reform. Health Syst Reform. 2018, Aug, 1;4(3):203\u201313.","journal-title":"Health Syst Reform"},{"issue":"1","key":"718_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12939-020-01168-6","volume":"19","author":"A Palacios","year":"2020","unstructured":"Palacios A, Espinola N, Rojas-Roque C. Need and inequality in the use of health care services in a fragmented and decentralized health system: evidence for Argentina. Int J Equity Health. 2020, Jul, 31;19(1):67.","journal-title":"Int J Equity Health"},{"key":"718_CR31","unstructured":"Banco Central de la Rep\u00fablica Argentina [Internet]. [https:\/\/www.bcra.gob.ar\/. cited 2023 Apr 24]. Available from."},{"key":"718_CR32","doi-asserted-by":"crossref","unstructured":"Palacios A, Balan D, Garay OU, Mena M, Souto A, Augustovski F, et al. HT3 base de costos unitarios en salud en argentina: una fuente de informaci\u00d3n continuamente actualizada para evaluaciones economicas y analisis de impacto presupuestario en un sistema de salud fragmentado. Value Health Reg Issues. 19:S8. Available from https:\/\/www.valuehealthregionalissues.com\/article\/S2212-1099(19)30142-6\/fulltext.","DOI":"10.1016\/j.vhri.2019.08.042"},{"issue":"2","key":"718_CR33","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.jacig.2023.100081","volume":"2","author":"JD Squire","year":"2023","unstructured":"Squire JD, Pitlick MM, Freeman CM, Joshi AY. Safety and tolerability of evusheld in patients with CVID: the mayo clinic experience. J Allergy Clin Immunol Global. 2023 May;2(2):100081.","journal-title":"The J Allergy And Clin Immunol Global"},{"issue":"4","key":"718_CR34","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s12325-021-01654-5","volume":"38","author":"D Sheinson","year":"2021","unstructured":"Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021, Apr;38(4):1811\u201331.","journal-title":"Adv Ther"},{"key":"718_CR35","unstructured":"de Poblaci\u00f3n SMCN, Hogares, Viviendas. El 60, 9% de la poblaci\u00f3n tiene obra social, prepaga o cobertura de PAMI - Censo Nacional de Poblaci\u00f3n, Hogares y Viviendas. Available from: 2023. https:\/\/censo.gob.ar\/index.php\/el-609-de-la-poblacion-tiene-obra-social-prepaga-o-cobertura-de-pami\/. cited 2025 Mar 18."},{"issue":"18","key":"718_CR36","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1002\/cncr.34354","volume":"128","author":"TA Ollila","year":"2022","unstructured":"Ollila TA, Masel RH, Reagan JL, Lu S, Rogers RD, Paiva KJ, et al. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. Cancer. 2022 Sep, 9;128(18):3319.","journal-title":"Cancer"},{"key":"718_CR37","doi-asserted-by":"publisher","unstructured":"Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Ichikawa H, Sakai H, et al. A third dose COVID-19 vaccination in allogeneic hematopoietic stem cell transplantation patients. Vaccines (Basel) [Internet]. 2022 Oct, 29;10(11). Available from: https:\/\/doi.org\/10.3390\/vaccines10111830.","DOI":"10.3390\/vaccines10111830"},{"key":"718_CR38","doi-asserted-by":"crossref","unstructured":"Shields AM, Faustini SE, Hill HJ, Al-Taei S, Tanner C, Ashford F, et al. SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study. J Clin Immunol [Internet]. 2022, Jul;42(5). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35420363\/. cited 2023 Mar 6.","DOI":"10.1007\/s10875-022-01231-7"},{"key":"718_CR39","unstructured":"Argentina.gob.ar [Internet]. 2017. https:\/\/www.argentina.gob.ar\/anmat. cited 2023 Apr 27]. ANMAT. Available from."},{"issue":"11","key":"718_CR40","doi-asserted-by":"publisher","first-page":"ofac579","DOI":"10.1093\/ofid\/ofac579","volume":"9","author":"HM Chun","year":"2022","unstructured":"Chun HM, Milligan K, Agyemang E, Ford N, Rangaraj A, Desai S, et al. A systematic review of COVID-19 vaccine antibody responses in people with HIV. Open Forum Infect Dis. 2022, Nov, 8;9(11):ofac579.","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"718_CR41","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.ekir.2022.07.007","volume":"7","author":"R Torres","year":"2022","unstructured":"Torres R, Toro L, Sanhueza ME, Lorca E, Ortiz M, Pefaur J, et al. Clinical efficacy of SARS-CoV-2 vaccination in hemodialysis patients. Kidney Int Rep. 2022, Oct;7(10):2176\u201385.","journal-title":"Kidney Int Rep"},{"key":"718_CR42","doi-asserted-by":"crossref","unstructured":"Mosconi G, Fantini M, Righini M, Flachi M, Semprini S, Hu L, et al. Efficacy of SARS-CoV-2 vaccination in dialysis patients: epidemiological analysis and Evaluation of the clinical progress. J Clin Med Res [Internet]. 2022, Aug, 12;11(16). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36012962\/. cited 2023 Mar 6.","DOI":"10.3390\/jcm11164723"},{"key":"718_CR43","doi-asserted-by":"publisher","first-page":"101642","DOI":"10.1016\/j.eclinm.2022.101642","volume":"53","author":"T Thomson","year":"2022","unstructured":"Thomson T, Prendecki M, Gleeson S, Martin P, Spensley K, De Aguiar RC, et al. Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients. EClinicalMedicine. 2022, Nov;53:101642.","journal-title":"EClinicalMedicine"},{"key":"718_CR44","doi-asserted-by":"crossref","unstructured":"Augustovski F, Bardach A, Santoro A, Rodriguez-Cairoli F, L\u00f3pez-Osornio A, Argento F, et al. Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina. In: Peru. Cost effectiveness and resource allocation : c\/E. Vol. 21. Brazil, Chile, Colombia, Costa Rica, Mexico; 2023 Apr 1. p. 21.","DOI":"10.1186\/s12962-023-00430-2"},{"key":"718_CR45","unstructured":"Argentina.gob.ar [Internet]. Dosis de refuerzo vacuna COVID-19. Available from: 2020. https:\/\/www.argentina.gob.ar\/coronavirus\/vacuna. cited 2023 Nov 16."},{"issue":"1","key":"718_CR46","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/TP.0000000000004411","volume":"107","author":"M Pinto-\u00c1lvarez","year":"2023","unstructured":"Pinto-\u00c1lvarez M, Fern\u00e1ndez-Ni\u00f1o JA, Arregoc\u00e9s-Castillo L, Rojas-Botero ML, Palacios AF, Galvis-Pedraza M, et al. Real-world evidence of COVID-19 vaccines effectiveness in Solid-organ transplant Recipient population in Colombia: a study nested in the esperanza cohort. Transplantation. 2023 Jan, 1;107(1):216\u201324.","journal-title":"Transplantation"},{"key":"718_CR47","unstructured":"World Bank Open Data [Internet]. [https:\/\/datos.bancomundial.org\/. cited 2023 Apr 24]. World Bank Open Data. Available from."},{"issue":"5","key":"718_CR48","first-page":"631","volume":"82","author":"G Rosa-Diez","year":"2022","unstructured":"Rosa-Diez G, Papaginovic Leiva MM, Lombi F, Crucelegui MS, Mart\u00ednez RD, Trimarchi H, et al. Safety and effectiveness of COVID-19 SPUTNIK V vaccine in dialysis patients. Medicina. 2022;82(5):631\u201340.","journal-title":"Medicina"},{"issue":"4","key":"718_CR49","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.ajkd.2022.10.010","volume":"81","author":"HJ Manley","year":"2023","unstructured":"Manley HJ, Li NC, Aweh GN, Hsu CM, Weiner DE, Miskulin D, et al. SARS-CoV-2 vaccine effectiveness and breakthrough infections among patients receiving maintenance dialysis. Am J Kidney Dis. 2023, Apr;81(4):406\u201315.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"718_CR50","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/annrheumdis-2021-221554","volume":"81","author":"D Simon","year":"2022","unstructured":"Simon D, Tascilar K, Fagni F, Schmidt K, Kr\u00f6nke G, Kleyer A, et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Ann Rheum Dis. 2022 Jul;81(7):1023\u201327.","journal-title":"Ann Rheum Dis"},{"key":"718_CR51","doi-asserted-by":"publisher","unstructured":"Lee ARYB, Wong SY, Tay SH. Booster COVID-19 vaccines for immune-mediated inflammatory disease patients: a systematic review and meta-analysis of efficacy and safety. Vaccines (Basel) [Internet]. 2022 Apr, 22;10(5). Available from: https:\/\/doi.org\/10.3390\/vaccines10050668.","DOI":"10.3390\/vaccines10050668"},{"issue":"6","key":"718_CR52","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","volume":"23","author":"LYW Lee","year":"2022","unstructured":"Lee LYW, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. Lancet Oncol. 2022, Jun;23(6):748\u201357.","journal-title":"Lancet Oncol"},{"issue":"15","key":"718_CR53","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.vaccine.2023.03.006","volume":"41","author":"ID Plumb","year":"2023","unstructured":"Plumb ID, Fette LM, Tjaden AH, Feldstein L, Saydah S, Ahmed A, et al. Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 infection, March-October, 2021. Vaccine. 2023 Apr, 6;41(15):2596\u2013604.","journal-title":"Vaccine"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00718-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00718-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00718-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:55:09Z","timestamp":1774616109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00718-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00718-z","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}